Table 1.
Variables | Total sample size (N = 140) |
---|---|
Age in years, mean (SD) | 60 (5.2) |
Race, N (%) | |
Caucasian | 132 (94.3%) |
Non-Caucasian | 8 (5.7%) |
Clinical stage, N (%) | |
cT1 | 32 (22.9%) |
cT2 | 97 (69.3%) |
cT3 | 9 (6.4%) |
Preoperative PSA in ng/ml, mean (SD) | 13.6 (14.3) |
Gleason score, N (%) | |
≤6 | 5 (3.6%) |
7 | 69 (49.3%) |
8–10 | 66 (47.1%) |
Organ-confined disease, N (%) | |
Yes | 13 (9.3%) |
No | 127 (90.7%) |
Extracapsular penetration, N (%) | |
Yes | 106 (75.7%) |
No | 34 (24.3%) |
Seminal vesicle invasion, N (%) | |
Yes | 64 (45.7%) |
No | 76 (54.3%) |
Lymph node involvement, N (%) | |
Yes | 52 (37.1%) |
No | 88 (62.9%) |
Surgical margins, N (%) | |
Positive | 46 (32.9%) |
Negative | 94 (67.1%) |
Time from prostatectomy to PSA recurrence, N (%) | |
≤3 years | 101 (72.1%) |
>3 years | 39 (27.9%) |
PSA doubling time (PSADT), N (%) | |
<3 months | 30 (21.4%) |
3–9 months | 60 (42.9%) |
9–15 months | 25 (17.9%) |
≥15 months | 25 (17.9%) |
Time from PSA recurrence to metastasis, N (%) | |
≤3 years | 81 (57.9%) |
>3 years | 59 (42.1%) |
Receipt of hormonal therapy (after metastasis), N (%) | |
Yes | 129 (92.1%) |
No | 11 (7.9%) |
Numbera of metastases at first presentation, N (%) | |
≤3 | 97 (72.9%) |
≥4 | 36 (27.1%) |
Site of first metastasis, N (%) | |
Bone | 124 (88.6%) |
Liver/lung/node | 16 (11.4%) |
Painb with first metastasis, N (%) | |
Yes | 38 (29.2%) |
No | 92 (70.8%) |
Receipt of bisphosphonate (after metastasis), N (%) | |
Yes | 62 (53.0%) |
No | 55 (47.0%) |
ECOG status at first metastasis, N (%) | |
≥1 | 27 (20.8%) |
0 | 103 (79.2%) |
aThe number of metastases was taken to be the combined number of soft tissue and osseous metastases as determined by CT and bone scan, respectively.
bThe presence of cancer-related pain was based on a pain score of ≥1/10 on a standard 0–10 pain scale.